Abstract
This session will present new knowledge related to pharmacological management of older adults with LLP. The first presentation will provide an overview of the existing randomized controlled trial evidence related to the use of antipsychotics in LLP. New evidence on the patterns of antipsychotics among older adults with LLP from a population-based real world study. This study will provide an overview of the characteristics of this population including medical and psychiatric comorbidity. The patterns of antipsychotic use will be described in this population including measures of polypharmacy and dosages. The second session will then present evidence on the association between patterns of antipsychotic use and all-cause mortality among older adults with LLP. This study will describe who various prescribing patterns and subpopulations of individuals with LLP who may be at increased risk of mortality in association with antipsychotics. The third presentation will focus on the use of long-acting injectable medications (LAIs) in older adults with LLP. The frequency with which LAI are used in older adults with LLP will be described along with the characteristics of older adults who are prescribed LAI and the patterns of LAI in this population. The final presentation will provide an overview of an integrated care pathway for older adults with LLP and present evidence for the utility of care pathways for older adults with LLP. Attendees will learn new information related to the use of antipsychotics in LLP and identify strategies to optimize prescribing for this vulnerable and growing population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
